Tadayoshi Hashimoto
Physician National Cancer Center Hospital East, Japan
Seminars
Tuesday 3rd February 2026
Introducing Myriad’s Ultra-Sensitive Tumor Informed MRD Assay
9:30 am
Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD testing is being applied across real clinical and development settings. Hear how leading experts are translating MRD data into actionable decisions across patient management, trial design, and therapeutic development. Walk away with a clear view of where MRD delivers value today and how to apply it across your own programs.
Thursday 5th February 2026
Clinical Utility of a Pan-Cancer WGS-based MRD Assay
10:00 am
- Explore the latest clinical data which has been generated using ultrasensitive MRD from a major pan-cancer study led in Japan
- Discuss real-world clinical use cases for a pan-cancer WGS-based MRD assay
- Share perspectives on applying ultrasensitive MRD testing in practice
